BSG BioNewsLetter 06#2002 - BioSeeker Group's analysis and products eNewsletter
URL: http://www.bioseeker.com http://www.bsg-online.biz
-- CONTENTS --
1) New Report: 'Fierce Competition for a Shrinking HCV Market?'
2) Three New Reports on the Swedish Biopharma Industry
3) New Report: 'The Next Generation Antifungals: Triazoles vs. Peptides'
4) Seek And You Will Find
5) Conference Opportunity
6) Coming reports: HCV Therapy / Winning the Osteoporosis Therapy Race
7) Subscription
8) BioSeeker Online Store
====================================================================
1) FIERCE COMPETITION FOR A SHRINKING HCV MARKET?
- A New Report from BioSeeker Group
Hepatitis C virus (HCV) has already caused a global epidemic, but the worst may yet be to come. Nearly 4 million people are or have been infected with HCV in the U.S. alone and a fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015.
The number of new infections per year, however, has declined from an average of 240,000 in the 1980s to about 25,000 in 2001. By 2020, almost all of the infected will have had the disease for more than 25 years. Between the years 2010 and 2020, most patients will then have reached an age of 55 to 75 years, many infected will die of other reasons before they will be diagnosed and started any anti-HCV therapy.
In this Highlight Report, BioSeeker has focused on three classes of therapeutic approaches as they represent different therapeutic strategies, but also as they target different time spans in the HCV market: immunomodulating substances, protease inhibitors, and vaccines. The report analyzes the short, mid-range and long-term market development by studying these therapeutic approaches in different developmental stages. we have tried to assess the competition between these therapeutic strategies and to correlate this with possible market development. Due to the high competition and a shrinking market some therapies will have difficulties to reach sufficient revenues within their lifecycle. Activities from a total of 50 companies are described.
For more information about this report, please visit http://www.bioseeker.com/index.asp?report=hcv1
====================================================================
2) THREE NEW REPORTS ON THE SWEDISH BIOPHARMA INDUSTRY
As an alternative to the complete report 'Swedish Biopharma Industry - The Next Wave', BioSeeker Group has now published three narrower reports focused on different aspects of the Swedish Biopharma Industry:
- In Depth Financial Report on the Swedish Biopharmaceutical Branch 2002
- R&D in Swedish Biopharma Companies 2002
- Swedish Biopharma Profiles 2002
For more information about these reports, please visit http://www.bioseeker.com/index.asp?report=swepharma_reports
====================================================================
3) THE NEXT GENERATION ANTIFUNGALS : TRIAZOLES VS PEPTIDES
- A New Report from BioSeeker Group
According to the Antifungal Work Group at NIH there is a "critical need for the development of antifungal agents". There will be tight competition for market shares when PfizerÕs patent on fluconazole (the active ingredient in Diflucan(TM)) expires in 2004. Both Bristol-Myers Squibb and Schering-Plough will try to compete for market shares. In this Highlight Report, we present new data on activites in the field of triazole and peptide antifungals. Topics considered in this report are :
- Research (spectrums, activities, side-effects, resistance and drug interactions)
- Patents
- Clinical trials (indications, status and activities)
- Partnerships
- Expected market launches and sales
For more information about this report, please visit http://www.bioseeker.com/index.asp?report=antifungal
====================================================================
4) SEEK AND YOU WILL FIND
Identify and locate your potential customers, competitors, and partners by using BioSeeker Group's world-wide company search service. This service is based on BioSeeker's in-house company database built up during four years of operation and containing more than 10,000 life science companies globally.
We offer you this service in 3 steps:
Step 1. Search & Identify (399 USD)
Step 2. Locate & Validate (699 USD)
Step 3. Select & Build (individual price). Choose the companies of interest and BSG builds extensive profiles of those.
For more information about this service, please contact us at bioinfo _ bioseeker.com
====================================================================
5) CONFERENCE OPPORTUNITY
BioBusiness 2003 is the premier bio-partnering event for biotech and pharma business development and licensing executives. At this senior-level international event you won't have to trawl through your 200 fellow attendees to find fellow business development and licensing professionals as these are the only biotech and pharma representatives coming! So instead of wasting your time looking for them, you can concentrate on discussing strategies with them in interactive roundtable groups or formulating future plans with them in private one-to-one meetings. Plus you can learn from the best! Hear from 16 leading pharmaceuticals and 15 world class biotechs, such as Novartis, F. Hoffman La Roche, Boehringer Ingelheim, Aventis, Genentech, Genzyme and Vertex Pharmaceuticals, who will tell you what they are currently looking for in business partners and how they see alliance and partnering strategies developing in the next five years. Book your place now!
For more information, please visit www.wbresearch.com/biobusiness or contact Colin Chapman (colin2^^^wbr.co.uk)
====================================================================
6) COMING REPORTS
- Complete Guide to Molecular Approaches for HCV Therapy
Treatment of HCV (Hepatitis C Virus) is a market with unmet medical needs, with relatively young people infected and a high risk for chronic disease. The coming decade will see exciting developments in HCV therapy thanks to breakthroughs in overcoming a major barrier to development: the lack of dedicated models suitable for validating candidate compounds in a low-cost, highthroughput format. BioSeeker Group has identified at least 115 companies with interest in various stages in the field of HCV therapy. Out of these 100, approximately 10 of the 'big pharma' are represented. Our coming report "Complete Guide to Molecular Approaches for HCV Therapy" analyses the field of new HCV therapeutics and assess possible outcomes for drugs and companies in this sector.
Please contact us at bioinfo(-)bioseeker.com for more information about this report.For further reading about HCV, please visit our free analytical article on this topic (http://www.bioseeker.com/docs/topics/topic_hcv.asp)
- Winning the Osteoporosis Therapy Race
Osteoporosis, deterioration of bone tissue and an increased risk of fractures, is considered by the World Health Organization to be second only to cardiovascular disease as a leading healthcare problem. According to other studies, sales of osteoporosis drugs in these markets totaled $3.4 billion in 2000, and are expected to reach $6.5 billion by 2005. A new class of osteoporosis therapies, designed to build bone mass in contrast to currently available anti-osteoporosis medicines are presently under study. These anabolic therapies consist of parathyroid hormone (FortÎoª and ALX-11) or fluoride to stimulate bone formation, but their safety and efficacy remain to be established. The first of these drugs to reach the market will probably be FortÎoª, known generically as teriparatide (recombinant parathyroid hormone).
Please contact us for more information about this report (bioinfo+/-bioseeker.com). For further reading about osteoporosis, please visit our free analytical article on this topic (http://www.bioseeker.com/docs/topics/topic_osteoporosis.asp)
====================================================================
7) SUBSCRIPTION
To continue to stay tuned with coming editions of BioSeeker Groups BioNewsLetter, please send an email to subscribe|*|bioseeker.com
============================================================================
8) BIOSEEKER ONLINE STORE
BioSeeker has now made it easy to order any of our products online, directly from our website. Visit www.bsg-online.biz to place an online order.
============================================================================
ADVERTISING
Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at sales*bioseeker.com for further information on how to advertise in BSG BioNewsletter.
COURTESY
If you would like to comment on our newsletter please send us an email to feedback.:.bioseeker.com
If you would like to be removed from our newsletter list, please reply to unsubscribe#%#bioseeker.com
Received on 2002-10-23 - 06:31 GMT
This archive was generated by hypermail 2.2.0 : 2005-11-24 - 10:21 GMT